Volver a la clasificación

Surgery Partners, Inc. (SGRY)

NEUTRAL
HealthcareMedical Care FacilitiesUnited States

Fundamental

54

Precio

$13.99

Capitalización Bursátil

$1.90B

Parte 1 · Cuánto vale la empresa

Resumen

Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. It offers emergency departments; ancillary services such as physician practices and diagnostic testing; multi-specialty physician practices; urgent care facilities; and anesthesia services. In addition, it offers single- and multi-specialty facilities. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Balance y Liquidez

Ingresos

$3.37B

Últimos 12 meses (hasta 30/6/2026)

Beneficio Neto

$-89M

Últimos 12 meses (hasta 30/6/2026)

Flujo de Caja Libre

$196M

Patrimonio Neto Total

$1.71B

Pasivo Total

$4.99B

Ratio de Liquidez

1.95

Cobertura de Intereses

-

Deuda/EBITDA

7.18

Beneficio Por Acción

Ingresos y Beneficio Neto

Flujo de Caja Libre

Desglose de Ingresos

Estado histórico

Márgenes en el tiempo

La deuda en el tiempo

Cuánto pesa la deuda

Cuadro de crecimiento

Crecimiento — Ingresos

Estimación de Valor Justo

General caseValoración Justa

Valor Justo

$17.17

Precio Actual

$13.99

Margen de Seguridad

+18.5%

Rango de Valor Justo

$14.82 - $19.53

Métodos de Estimación

Analyst price target:$18.73
Discounted cash flow (DCF):$17.06
Earnings multiple (P/E):Not enough data to compute it
Graham growth formula:Not enough data to compute it
Earnings power value (EPV):$11.29
Justified P/B:Not enough data to compute it
Dividend discount (Gordon):Not enough data to compute it
P/FFO, funds from operations:Not enough data to compute it
Mid-cycle earnings:$70.60
Revenue multiple:Not enough data to compute it
Consenso de Analistas:Compra Fuerte (14B / 4H / 0S)
Última Sorpresa de Resultados:+68.07%

Métricas de Valoración

Ratio P/E

-

ROE

-4.5%

Ratio P/B

1.09

P/FCF

9.74

Margen Bruto

-

ROIC

4.1%

Radar de Rentabilidad

Value Creation (Economic Moat)

ROIC

4.1%

WACC

4.9%

ROIC − WACC

-0.9 pp

ROIC is roughly in line with the cost of capital — the company is barely covering its capital cost.

Criterios de Análisis Fundamental

Superado (12)

  • P/FCF 9.74
  • P/B Ratio 1.09
  • Debt/Equity ratio
  • Operating Margin 11.4%
  • Positive Free Cash Flow
  • Current Ratio
  • Revenue Growth 5Y 12.2%
  • Analyst Consensus 78% Buy
  • Earnings Surprise avg 14.8%
  • Share Dilution 1.0%
  • Net Margin Trend -2.6% vs -5.6%
  • Piotroski F-Score 5/9

Fallido (9)

  • EPS shows upward trend
  • Price CAGR -0.87%
  • ROIC 4.1%
  • CapEx intensity
  • Debt/EBITDA
  • Return on Tangible Assets
  • Low reliance on intangibles
  • DCF valuation (Fairly valued)
  • ROE -5.3%

No disponible (6)

  • Gross Margin NaN%
  • Dividend Payout NaN%
  • Interest Coverage
  • Price below Graham Number
  • PEG Ratio (need PE > 0 and growth > 0)
  • Earnings Quality (OCF/Net Income)

Piotroski F-Score

5/9

Señales mixtas: algunas áreas requieren atención

score
criteria

Calidad de los Beneficios

-

Baja calidad: investigue la contabilidad

Dilución de Acciones

1.0%

El número de acciones es estable

Gobernanza

Equipo Directivo

NombreCargoEdad
Mr. J. Eric EvansCEO & Director48
Mr. David T. Doherty CPAExecutive VP & CFO53
Ms. Jennifer B. Baldock J.D.Executive VP and Chief Administrative & Development Officer54
Ms. Marissa A. BrittenhamExecutive VP & Chief Strategy Officer40
Mr. W. Trent WebbDivision President South45
Mr. Justin R. OppenheimerExecutive VP & COO40
Mr. Jon FredricksonSenior VP & Chief Information Officer-
Ms. Roxanne WomackSenior VP & Chief Compliance Officer-
Mr. Spencer ClarkGeneral Counsel & Senior VP-
Ms. Danielle BurkhalterExecutive VP & Chief Human Resources Officer40

Riesgo de Auditoría

9

Riesgo del Consejo

6

Riesgo de Compensación

4

Riesgo de Derechos del Accionista

8

Parte 2 · El precio y el momento de entrar

Esta parte no sirve para saber si la empresa vale: sirve para elegir cuándo comprarla, una vez que los fundamentales te han convencido. Dentro: análisis técnico, potencial, caídas históricas, exposición gamma.

Latest News

Recent headlines for SGRY, sourced from Markets Gazette.

  • 3/3/2026NEGATIVE
    Surgery Partners Stock Hits 52-Week Low - Here's Why

    Markets Gazette reports a significant downturn for Surgery Partners, whose shares (SGRY) hit a new 52-week low in premarket trading. The decline was triggered by the release of financial results that fell short of analysts' expectations. Furthermore, the company provided a cautious outlook for 2026, fueling investor concerns regarding future growth and profitability. This development suggests downward pressure on the stock, with the market reacting negatively to both current performance and near-term prospects. Investors should closely monitor the evolution of the company's strategy and upcoming reports to assess any signs of recovery.

  • 2/23/2026NEGATIVE
    Surgery Partners Stock Down 39% as One Fund Slashes Stake by $19 Million

    Shares of Surgery Partners, a healthcare firm operating a national network of surgical centers, plummeted by a staggering 39%. The sharp decline was triggered by news that a major investment fund slashed its stake in the company, selling off shares worth $19 million. Such a substantial divestment by an institutional investor is a significant red flag for the market, often interpreted as a loss of confidence in the company's future prospects or valuation. This large-scale sell-off has created immense downward pressure on the stock, reflecting widespread investor concern. Traders will now be closely watching for any follow-up from the company or further signs of institutional selling to gauge the underlying reasons for the fund's exit.

via Markets Gazette